Among patients with previous sinus surgery for chronic rhinosinusitis with nasal polyps, the number of past surgeries did not ...

GSK’s application is underpinned by the positive outcomes from the Phase III MATINEE trial, which demonstrated a significant ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted for review its application to expand the use of Nucala (mepolizumab), a monoclonal antibody that targets ...

EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment: London, UK Wednesday, March 26, 2025, 11:00 Hrs [IST] GSK plc announced that the European Me ...

(Alliance News) - GSK PLC on Monday said it has had an application to expand the use of mepolizumab for the treatment of chronic obstructive pulmonary disease accepted for review by the European ...

GSK said on Monday that the European Medicines Agency has accepted its application to expand the use of ‘Nucala’, or ...

GSK (GSK) plc announced that the European Medicines Agency has accepted for review its application to expand the use of Nucala, a monoclonal ...

The European Medicines Agency will review GSK's request to approve its asthma drug Nucala as an additional treatment for ...

London open The FTSE 100 is expected to open 28 points higher on Monday, having closed down 0.63% on Friday at 8,646.79.

The European Medicines Agency accepts GSK's regulatory filing for expanded use of Nucala to treat COPD for review.